CORMEDIX INC. Selling, General and Administrative Expense
CORMEDIX INC. (CRMD) reported Selling, General and Administrative Expense of $15.05 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2024-05-09
- CORMEDIX INC. selling, general and administrative expense for the quarter ending 2024-03-31 was $15.05M, a 97.75% increase year-over-year.
- CORMEDIX INC. selling, general and administrative expense for the quarter ending 2023-12-31 was $13.38M, a 139.98% increase year-over-year.
- CORMEDIX INC. selling, general and administrative expense for the quarter ending 2023-09-30 was $7.80M, a 68.61% increase year-over-year.
- CORMEDIX INC. selling, general and administrative expense for the quarter ending 2023-06-30 was $7.01M, a 38.76% increase year-over-year.
- CORMEDIX INC. selling, general and administrative expense for fiscal 2023 was $35.80M, a 78.96% increase from fiscal 2022.
- CORMEDIX INC. selling, general and administrative expense for fiscal 2022 was $20.01M, a 22.39% increase from fiscal 2021.
- CORMEDIX INC. selling, general and administrative expense for fiscal 2021 was $16.35M, a 17.79% increase from fiscal 2020.
- CORMEDIX INC. selling, general and administrative expense for fiscal 2020 was $13.88M, a 40.68% increase from fiscal 2019.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 9 month as first filed | Selling, General and Administrative Expense 12 month | Selling, General and Administrative Expense 92 month |
|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | $15.05M 10-Q · filed 2024-05-09 | $28.43M derived: sum of 2 quarters · filed 2024-05-09 | $36.23M derived: sum of 3 quarters · filed 2024-05-09 | $43.24M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2023-12-31 | $13.38M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $21.18M derived: sum of 2 quarters · filed 2024-03-12 | $28.19M derived: sum of 3 quarters · filed 2024-03-12 | $35.80M 10-K · filed 2024-03-12 | ||||
| 2023-09-30 | $7.80M 10-Q · filed 2023-11-14 | $14.81M derived: sum of 2 quarters · filed 2023-11-14 | $22.42M 10-Q · filed 2023-11-14 | $28.00M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2023-06-30 | $7.01M 10-Q · filed 2023-08-08 | $14.62M 10-Q · filed 2023-08-08 | $20.19M derived: sum of 3 quarters · filed 2024-05-09 | $24.82M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2023-03-31 | $7.61M 10-Q · filed 2024-05-09 | $13.18M derived: sum of 2 quarters · filed 2024-05-09 | $17.81M derived: sum of 3 quarters · filed 2024-05-09 | $22.86M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $5.58M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $10.20M derived: sum of 2 quarters · filed 2024-03-12 | $15.26M derived: sum of 3 quarters · filed 2024-03-12 | $20.01M 10-K · filed 2024-03-12 | ||||
| 2022-09-30 | $4.63M 10-Q · filed 2023-11-14 | $9.68M derived: sum of 2 quarters · filed 2023-11-14 | $14.43M 10-Q · filed 2023-11-14 | $18.98M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | $5.05M 10-Q · filed 2023-08-08 | $9.80M 10-Q · filed 2023-08-08 | $14.36M derived: sum of 3 quarters · filed 2023-08-08 | $18.19M derived: sum of 4 quarters · filed 2023-08-08 | ||||
| 2022-03-31 | $4.75M 10-Q · filed 2023-05-15 | $9.30M derived: sum of 2 quarters · filed 2023-05-15 | $13.14M derived: sum of 3 quarters · filed 2023-05-15 | $16.50M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | $4.55M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $8.39M derived: sum of 2 quarters · filed 2023-03-30 | $11.75M derived: sum of 3 quarters · filed 2023-03-30 | $16.35M 10-K · filed 2023-03-30 | ||||
| 2021-09-30 | $3.84M 10-Q · filed 2022-11-10 | $7.19M derived: sum of 2 quarters · filed 2022-11-10 | $11.79M 10-Q · filed 2022-11-10 | $15.58M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | $3.36M 10-Q · filed 2022-08-11 | $7.96M 10-Q · filed 2022-08-11 | $11.75M derived: sum of 3 quarters · filed 2022-08-11 | $15.44M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $4.60M 10-Q · filed 2022-05-12 | $8.39M derived: sum of 2 quarters · filed 2022-05-12 | $12.08M derived: sum of 3 quarters · filed 2022-05-12 | $15.31M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $3.79M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $7.48M derived: sum of 2 quarters · filed 2022-03-29 | $10.71M derived: sum of 3 quarters · filed 2022-03-29 | $13.88M 10-K · filed 2022-03-29 | ||||
| 2020-09-30 | $3.69M 10-Q · filed 2021-11-09 | $6.92M derived: sum of 2 quarters · filed 2021-11-09 | $10.09M 10-Q · filed 2021-11-09 | $12.77M derived: sum of 4 quarters · filed 2021-11-09 | ||||
| 2020-06-30 | $3.23M 10-Q · filed 2021-08-12 | $6.40M 10-Q · filed 2021-08-12 | $9.08M derived: sum of 3 quarters · filed 2021-08-12 | $11.71M derived: sum of 4 quarters · filed 2021-08-12 | ||||
| 2020-03-31 | $3.17M 10-Q · filed 2021-05-13 | $5.84M derived: sum of 2 quarters · filed 2021-05-13 | $8.47M derived: sum of 3 quarters · filed 2021-05-13 | $11.05M derived: sum of 4 quarters · filed 2021-05-13 | ||||
| 2019-12-31 | $2.68M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $5.31M derived: sum of 2 quarters · filed 2021-03-30 | $7.88M derived: sum of 3 quarters · filed 2021-03-30 | $9.87M 10-K · filed 2021-03-30 | ||||
| 2019-09-30 | $2.63M 10-Q · filed 2020-11-05 | $5.20M derived: sum of 2 quarters · filed 2020-11-05 | $7.19M 10-Q · filed 2020-11-05 | $9.40M derived: sum of 4 quarters · filed 2020-11-05 | ||||
| 2019-06-30 | $2.57M 10-Q · filed 2020-08-10 | $4.56M 10-Q · filed 2020-08-10 | $6.77M derived: sum of 3 quarters · filed 2020-08-10 | $8.78M derived: sum of 4 quarters · filed 2020-08-10 | ||||
| 2019-03-31 | $1.98M 10-Q · filed 2020-05-11 | $4.20M derived: sum of 2 quarters · filed 2020-05-11 | $6.21M derived: sum of 3 quarters · filed 2020-05-11 | $8.16M derived: sum of 4 quarters · filed 2020-05-11 | ||||
| 2018-12-31 | $2.21M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $4.23M derived: sum of 2 quarters · filed 2020-03-16 | $6.17M derived: sum of 3 quarters · filed 2020-03-16 | $8.07M 10-K · filed 2020-03-16 | ||||
| 2018-09-30 | $2.01M 10-Q · filed 2019-11-14 | $3.96M derived: sum of 2 quarters · filed 2019-11-14 | $5.86M 10-Q · filed 2019-11-14 | |||||
| 2018-06-30 | $1.95M 10-Q · filed 2019-08-14 | $3.85M 10-Q · filed 2019-08-14 | ||||||
| 2018-03-31 | $1.90M 10-Q · filed 2019-05-13 | |||||||
| 2017-09-30 | $1.99M 10-Q · filed 2018-11-14 | $4.04M derived: sum of 2 quarters · filed 2018-11-14 | $6.68M 10-Q · filed 2018-11-14 | |||||
| 2017-06-30 | $2.05M 10-Q · filed 2018-08-14 | $4.69M 10-Q · filed 2018-08-14 | ||||||
| 2017-03-31 | $2.64M 10-Q · filed 2018-05-15 | |||||||
| 2016-09-30 | $2.32M 10-Q · filed 2017-11-09 | $4.29M derived: sum of 2 quarters · filed 2017-11-09 | $6.45M 10-Q · filed 2017-11-09 | |||||
| 2016-06-30 | $1.97M 10-Q · filed 2017-08-09 | $4.13M 10-Q · filed 2017-08-09 | ||||||
| 2016-03-31 | $2.05M 10-Q · filed 2017-05-10 | $2.16M 10-Q · filed 2016-05-10 | ||||||
| 2015-09-30 | $2.95M 10-Q · filed 2016-11-09 | $5.30M derived: sum of 2 quarters · filed 2016-11-09 | $8.00M 10-Q · filed 2016-11-09 | $9.58M 10-Q · filed 2015-11-12 | ||||
| 2015-06-30 | $2.36M 10-Q · filed 2016-08-04 | $5.05M 10-Q · filed 2016-08-04 | $6.63M 10-Q · filed 2015-08-06 | |||||
| 2015-03-31 | $2.69M 10-Q · filed 2016-05-10 | $4.28M 10-Q · filed 2015-05-07 | ||||||
| 2014-09-30 | $1.59M 10-Q · filed 2015-11-12 | $3.29M derived: sum of 2 quarters · filed 2015-11-12 | $5.80M 10-Q · filed 2015-11-12 | |||||
| 2014-06-30 | $1.70M 10-Q · filed 2015-08-06 | $4.22M 10-Q · filed 2015-08-06 | ||||||
| 2014-03-31 | $2.51M 10-Q · filed 2015-05-07 | $18.78M 10-Q · filed 2014-05-15 | ||||||
| 2013-09-30 | $504.53K 10-Q · filed 2014-11-13 | $1.41M derived: sum of 2 quarters · filed 2014-11-13 | $1.97M 10-Q · filed 2014-11-13 | |||||
| 2013-06-30 | $908.74K 10-Q · filed 2014-08-14 | $1.46M 10-Q · filed 2014-08-14 | ||||||
| 2013-03-31 | $551.74K 10-Q · filed 2014-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |